# Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Study · id `cardio:ct-nct01938248` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01938248](<https://clinicaltrials.gov/study/NCT01938248>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01938248

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4012 participants.

## Technical summary

Registry record NCT01938248. Randomized; quadruple masking; primary purpose prevention. Start 2015-05 (actual); primary completion 2023-10-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 4012 participants (enrolled count; ClinicalTrials.gov record NCT01938248, source copy `cardio:ctgov-nct01938248-2023-11-15`, retrieved 2026-10-26)
- Started: 2015-05 (actual) (ClinicalTrials.gov record NCT01938248, source copy `cardio:ctgov-nct01938248-2023-11-15`, retrieved 2026-10-26)
- Primary completion: 2023-10-27 (actual) (ClinicalTrials.gov record NCT01938248, source copy `cardio:ctgov-nct01938248-2023-11-15`, retrieved 2026-10-26)
- Completion: 2023-11-03 (actual) (ClinicalTrials.gov record NCT01938248, source copy `cardio:ctgov-nct01938248-2023-11-15`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; Czechia; Denmark; Germany; Hungary; Italy; Netherlands; Norway; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT01938248, source copy `cardio:ctgov-nct01938248-2023-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01938248-2023-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
- Acronym: ARTESiA
- Condition: Atrial Fibrillation
- Condition: Stroke
- Intervention (Drug): Apixaban
- Intervention (Drug): aspirin
- Lead sponsor: Population Health Research Institute
- Lead sponsor class: OTHER
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY
- Collaborator: Medtronic
- Collaborator class: INDUSTRY
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Population Health Research Institute (`cardio:org-population-health-research-institute`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (`cardio:pubmed-37952132`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA (`cardio:pubmed-39019530`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial (`cardio:pubmed-39229707`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial (`cardio:pubmed-39862882`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial (`cardio:pubmed-41222953`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0f6b690d60fcd9461641bd2ab246cd486b9aa68d06f6bfa84fa8dfc034480dfe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
